The Global Health Body Sounds Alert Over Acute Scarcity of Obesity Jabs

Under a tenth of patients eligible to benefit from GLP-1 drugs such as Wegovy are able to get them, states the WHO as it releases its first recommendations on the drugs.

With in excess of 1,000,000,000 people worldwide currently living with obesity, it is calling for more widespread and fairer access to GLP-1 medication.

According to projections, in excess of 2,000,000,000 will be obese by 2030 if no action is taken.

"The latest guidelines recognises that excess weight is a lifelong illness that can be managed with comprehensive and continuous support," said WHO director-general Tedros Adhanom Ghebreyesus.

Substantial prices, limited production capacity, and supply-chain constraints are significant obstacles to widespread access to the treatments that can help people shift substantial weight, explains the agency.

GLP-1 Therapy Supply Crisis

Even in the present most optimistic scenario, the supply of GLP-1 therapies would only suffice for about 100 million people – less than 10% of those who need them, as stated by the health organization.

The guideline calls on governments and firms to widen availability, by approaches such as voluntary licensing.

Exclusive production rights on the active ingredient – the primary ingredient of a leading brand – is set to lapse in a number of countries in 2026.

The Way Obesity Jabs Work

These medications replicate a biological compound to slow digestion, reduce hunger and enhance the sense of being full so users eat less.

Individuals typically start to lose weight after several weeks of starting on the regular doses.

Evidence suggests patients may put most of the weight back on after a year of halting the medication, when their typical food cravings come back.

To be carrying excess weight elevates your chance for contracting diseases, such as type 2 diabetes, heart disease, brain attack, and certain malignancies.

Obesity affects people in countries worldwide and was linked to millions of fatalities worldwide in 2024, as per the health agency.